WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...
Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing Phase 2 trial for NTLA-2002, a CRISPR-based gene editing therapy for an ...
CRISPR Therapeutics and Vertex Pharmaceuticals have reported a consistent and sustained positive response in 10 patients treated for a pair of blood disorders—sickle-cell disease (SCD) and beta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results